Economic Evaluation of the InTENSE Program of Therapy Alongside Botulinum Neurotoxin a for the Rehabilitation of Chronic Upper Limb Spasticity
Toxins · 2025
DOI: 10.3390/toxins17070341 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, 2025. Verfasst von Rachel Milte und 8 weiteren Autor:innen. Beteiligte Einrichtung: Caring Futures Institute, Flinders University, Adelaide, SA 5001, Australia. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Muscle Spasticity, Upper Extremity, Neuromuscular Agents. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, National Heart Foundation of Australia.
Abstract (Originalsprache)
Spasticity is a persistent and debilitating consequence of stroke and effective rehabilitation is a healthcare priority. Botulinum neurotoxin A (BoNT-A) with supportive therapy has increasingly been embedded within clinical practice for treatment of post-stroke spasticity. But the evidence for this approach has hitherto been limited to the findings of a limited number of small trials. The InTENSE trial was undertaken specifically to provide high-quality clinical trial evidence focusing on the effect of BoNT-A and adjunctive therapy on upper limb spasticity. While the clinical trial did not detect a significant impact upon clinical outcomes, there remains a need to evaluate any impact on the broader use of healthcare resources and overall cost-effectiveness. A detailed cost–utility analysis of the InTENSE trial was undertaken. The costs over the 12-month follow-up period were compared with quality-adjusted life years (QALY) gained using utilities generated from the EQ-5D three level (EQ-5D-3L) instrument. There were no significant differences in QALY gained between the intervention and control groups identified, or in the majority of health and community care costs. The Incremental Cost-Effectiveness Ratio per QALY gained was estimated at AU $63,947.11 (Australian dollars), which is well above accepted thresholds for cost-effectiveness in Australia. The study was unable to identify evidence for the cost-effectiveness of treatment approaches combining BoNT-A with adjunctive therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Caring Futures Institute, Flinders University, Adelaide, SA 5001, Australia.
- School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia.
- Sydney School of Health Sciences, University of Sydney, Sydney, NSW 2006, Australia.
- College of Medicine and Public Health, Flinders University, Adelaide, SA 5001, Australia.
- School of Health Sciences, University of Newcastle, Callaghan, NSW 2308, Australia.
- Department of Neuroscience, Monash University, Alfred Health, Melbourne, VIC 304, Australia.
ORCID-Profile: Jia Song, Sean Docking, Ian D Cameron, Louise Ada, Coralie English, Natasha A Lannin
Förderung
- National Health and Medical Research Council
- National Heart Foundation of Australia
Zitieren
APA
Milte, R., Song, J., Docking, S., Ratcliffe, J., Cameron, I. D., Crotty, M., Ada, L., English, C., & Lannin, N. A. (2025). Economic Evaluation of the InTENSE Program of Therapy Alongside Botulinum Neurotoxin a for the Rehabilitation of Chronic Upper Limb Spasticity. Toxins. https://doi.org/10.3390/toxins17070341
Vancouver
Milte R, Song J, Docking S, Ratcliffe J, Cameron ID, Crotty M, et al. Economic Evaluation of the InTENSE Program of Therapy Alongside Botulinum Neurotoxin a for the Rehabilitation of Chronic Upper Limb Spasticity. Toxins. 2025. doi:10.3390/toxins17070341
BibTeX
@article{Milte2025,
author = {Milte, Rachel and Song, Jia and Docking, Sean and Ratcliffe, Julie and Cameron, Ian D and Crotty, Maria and Ada, Louise and English, Coralie and Lannin, Natasha A},
title = {Economic Evaluation of the InTENSE Program of Therapy Alongside Botulinum Neurotoxin a for the Rehabilitation of Chronic Upper Limb Spasticity},
journal = {Toxins},
year = {2025},
doi = {10.3390/toxins17070341}
}
EUVIMED